Irbesartan/Hydrochlorothiazide Stada

Irbesartan, the active ingredient in Irbesartan/Hydrochlorothiazide Stada, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients. GNH USA supplies Irbesartan/Hydrochlorothiazide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin system and renal sodium handling to lower elevated blood pressure. - Hypertension: provides effective blood pressure reduction in patients with primary hypertension. - Hypertension with volume overload: adds diuretic effect to improve control when fluid retention is present. - Resistant hypertension: offers an additional therapeutic option when monotherapy is insufficient.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia (especially with potassium‑sparing agents) - Angioedema or severe allergic reaction - Significant hypotension - Elevated liver enzymes or hepatic dysfunction

Irbesartan/Hydrochlorothiazide should be used with clinical monitoring and patient education. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function: assess serum creatinine and eGFR before initiation and during therapy. - Electrolyte balance: monitor potassium and sodium levels, especially when combined with other diuretics. - Pregnancy: avoid use; potential risk to fetus is unknown. - Concomitant drugs: review for interactions that may increase potassium or affect renal function. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines that affect blood pressure, renal function, or electrolyte balance. Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin inhibition can cause renal impairment. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: increased lithium levels and toxicity. - ACE inhibitors or other ARBs: additive effect on blood pressure and renal function. - NSAIDs: may reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may cause additive hypotensive effect. - CYP2C9 inhibitors (e.g., fluconazole): can increase irbesartan plasma concentrations. - Loop diuretics: enhanced diuretic effect and electrolyte loss. - Antidiabetic agents: blood glucose may be affected by changes in renal function.